Renaissance Technologies (RenTech)'s ARWR Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.04 M shares of Arrowhead Pharmaceuticals, Inc. (ARWR) worth $64.99 M, representing 0.10% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in ARWR, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 1.04 M shares. Largest reduction occurred in Q2 2020, reducing 666,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Arrowhead Pharmaceuticals (ARWR) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arrowhead Pharmaceuticals (ARWR) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.04 M | New Buy | 1.04 M | $62.70 |
| Q4 2024 | -231,300 | Sold Out | 0 | $0.00 |
| Q3 2024 | +231,300 | New Buy | 231,300 | $19.37 |
| Q1 2024 | -122,000 | Sold Out | 0 | $0.00 |
| Q4 2023 | -259,500 | Reduce 68.02% | 122,000 | $30.60 |
| Q3 2023 | -3,400 | Reduce 0.88% | 381,500 | $26.87 |
| Q2 2023 | +92,100 | Add 31.45% | 384,900 | $0.04 |
| Q1 2023 | -201,000 | Reduce 40.70% | 292,800 | $0.03 |
| Q4 2022 | -261,600 | Reduce 34.63% | 493,800 | $0.04 |
| Q3 2022 | +314,400 | Add 71.29% | 755,400 | $33.05 |
| Q2 2022 | +60,700 | Add 15.96% | 441,000 | $35.21 |
| Q1 2022 | +380,300 | New Buy | 380,300 | $45.99 |
| Q4 2021 | -54,100 | Sold Out | 0 | $0.00 |
| Q3 2021 | -125,100 | Reduce 69.81% | 54,100 | $62.42 |
| Q2 2021 | -62,400 | Reduce 25.83% | 179,200 | $82.82 |
| Q1 2021 | +241,600 | New Buy | 241,600 | $66.31 |
| Q2 2020 | -666,400 | Sold Out | 0 | $0.00 |
| Q1 2020 | -55,900 | Reduce 7.74% | 666,400 | $28.77 |
| Q4 2019 | +64,700 | Add 9.84% | 722,300 | $63.43 |
| Q3 2019 | -131,200 | Reduce 16.63% | 657,600 | $28.18 |
| Q2 2019 | +618,400 | Add 362.91% | 788,800 | $26.50 |
| Q1 2019 | +170,400 | New Buy | 170,400 | $18.35 |
| Q3 2017 | -374,164 | Sold Out | 0 | $0.00 |
| Q2 2017 | +374,164 | New Buy | 374,164 | $1.62 |
Renaissance Technologies (RenTech)'s Arrowhead Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased Arrowhead Pharmaceuticals, Inc. (ARWR) in Q2 2017, acquiring 374,164 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Arrowhead Pharmaceuticals, Inc. (ARWR) for 24 quarters since Q2 2017.
Renaissance Technologies (RenTech)'s largest addition to Arrowhead Pharmaceuticals, Inc. (ARWR) was in Q1 2026, adding 1,036,495 shares worth $64.99 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,036,495 shares of Arrowhead Pharmaceuticals, Inc. (ARWR), valued at approximately $64.99 M.
As of the Q1 2026 filing, Arrowhead Pharmaceuticals, Inc. (ARWR) represents approximately 0.10% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Arrowhead Pharmaceuticals, Inc. (ARWR) was 1,036,495 shares, as reported at the end of Q1 2026.